General Information of Disease (ID: DISJE0UU)

Disease Name Generalized epilepsy with febrile seizures plus
Synonyms
generalized epilepsy with febrile seizures-plus; generalised epilepsy with febrile seizures-plus; genetic epilepsy with febrile seizures plus; genetic epilepsy with febrile seizures-plus; GEFS+; generalized epilepsy with febrile seizures plus; epilepsy, generalized, with febrile seizures plus
Definition
A familial epilepsy syndrome in which family members display a seizure disorder from the generalized epilepsy with febrile seizures plus spectrum which ranges from simple febrile seizures (FS) to the more severe phenotype of myoclonic-astatic epilepsy (MAE) or Dravet syndrome (DS).
Disease Hierarchy
DISD715V: Hereditary neurological disease
DISBB28L: Epilepsy
DISJE0UU: Generalized epilepsy with febrile seizures plus
Disease Identifiers
MONDO ID
MONDO_0018214
MESH ID
C565808
UMLS CUI
C3502809
MedGen ID
503203
Orphanet ID
36387
SNOMED CT ID
699688008

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 9 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
GABRG2 TT06RH5 Supportive Autosomal dominant [1]
ADRA1D TT34BHT Strong Genetic Variation [2]
GABRD TTGXH6N Strong Genetic Variation [3]
GABRG2 TT06RH5 Strong Genetic Variation [4]
HCN1 TTNB6UQ Strong GermlineCausalMutation [5]
KCNA1 TTS3DIK Strong Genetic Variation [6]
KCNQ3 TTIVDM3 Strong Genetic Variation [7]
SCN2A TTLJTUF Strong Genetic Variation [8]
HCN1 TTNB6UQ Definitive Autosomal dominant [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SCN1A DTN0M1I Definitive Autosomal dominant [9]
------------------------------------------------------------------------------------
This Disease Is Related to 6 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADGRV1 OTLVXHHP Limited Genetic Variation [10]
GABRG2 OTGNDWUO Supportive Autosomal dominant [1]
HCN1 OTVOWKQ7 Definitive Autosomal dominant [9]
SCN1A OTJ9ZTYI Definitive Autosomal dominant [9]
SCN1B OTGD78J3 Definitive Autosomal dominant [9]
STX1B OTSW59X0 Definitive Autosomal dominant [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 Clinical Practice Guidelines for Rare Diseases: The Orphanet Database. PLoS One. 2017 Jan 18;12(1):e0170365. doi: 10.1371/journal.pone.0170365. eCollection 2017.
2 Sodium channel dysfunction in intractable childhood epilepsy with generalized tonic-clonic seizures.J Physiol. 2005 Dec 1;569(Pt 2):433-45. doi: 10.1113/jphysiol.2005.094326. Epub 2005 Oct 6.
3 Mutations in GABAA receptor subunits associated with genetic epilepsies.J Physiol. 2010 Jun 1;588(Pt 11):1861-9. doi: 10.1113/jphysiol.2010.186999. Epub 2010 Mar 22.
4 A novel GABRG2 mutation, p.R136*, in a family with GEFS+ and extended phenotypes.Neurobiol Dis. 2014 Apr;64:131-141. doi: 10.1016/j.nbd.2013.12.013. Epub 2014 Jan 7.
5 HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond. Brain. 2018 Nov 1;141(11):3160-3178. doi: 10.1093/brain/awy263.
6 Ion channels and epilepsy.Am J Med Genet. 2001 Summer;106(2):146-59. doi: 10.1002/ajmg.1582.
7 Impact of our understanding of the genetic aetiology of epilepsy.J Neurol. 2000 May;247(5):327-34. doi: 10.1007/s004150050598.
8 Confirming an expanded spectrum of SCN2A mutations: a case series.Epileptic Disord. 2014 Mar;16(1):13-8. doi: 10.1684/epd.2014.0641.
9 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
10 A nonsense mutation of the MASS1 gene in a family with febrile and afebrile seizures.Ann Neurol. 2002 Nov;52(5):654-7. doi: 10.1002/ana.10347.